New drug trial seeks to control aggressive blood cancers
NCT ID NCT06761677
Summary
This study is testing an intravenous drug called brincidofovir in people whose lymphoma has come back or hasn't responded to previous chemotherapy. The main goals are to find a safe dose and see if the drug can help shrink tumors. The trial is currently suspended and was planned to enroll up to 43 participants with specific types of lymphoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY LYMPHOMA INCLUDING ENKL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Institute Hospital Of JFCR
Kōtoku, Japan
-
Kyoto University Hospital
Kyoto, Japan
-
Mie University Hospital
Tsu, Japan
-
National Cancer Center Hospital
Chūōku, Japan
-
National Cancer Centre Singapore
Singapore, Singapore
-
Okayama University Hospital
Okayama, Japan
-
Queen Mary Hospital
Hong Kong, China
-
Tokyo Metropolitan Komagome Hospital
Bunkyō City, Japan
Conditions
Explore the condition pages connected to this study.